Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Risk factors for pneumococcal nasopharyngeal colonization before and after pneumococcal conjugate vaccination in persons with HIV: brief report.

Öbrink-Hansen K, Søgaard OS, Harboe ZB, Schønheyder HC.

Curr HIV Res. 2012 Apr;10(3):252-5.

PMID:
22384845
2.

The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.

Thanee C, Pancharoen C, Likitnukul S, Luangwedchakarn V, Umrod P, Phasomsap C, Apornpong T, Chuanchareon T, Butterworth O, Puthanakit T.

Vaccine. 2011 Aug 11;29(35):5886-91. doi: 10.1016/j.vaccine.2011.06.072. Epub 2011 Jul 3. Erratum in: Vaccine. 2011 Oct 26;29(46):8470.

PMID:
21729732
4.

Cross-sectional study of nasopharyngeal carriage of Streptococcus pneumoniae in human immunodeficiency virus-infected adults in the conjugate vaccine era.

Onwubiko C, Swiatlo E, McDaniel LS.

J Clin Microbiol. 2008 Nov;46(11):3621-5. doi: 10.1128/JCM.01245-08. Epub 2008 Sep 24.

5.

Nasopharyngeal carriage of Streptococcus pneumoniae in Taiwan before and after the introduction of a conjugate vaccine.

Kuo CY, Hwang KP, Hsieh YC, Cheng CH, Huang FL, Shen YH, Huang YC, Chiu CH, Chen PY, Lin TY.

Vaccine. 2011 Jul 18;29(32):5171-7. doi: 10.1016/j.vaccine.2011.05.034. Epub 2011 May 27.

PMID:
21621578
6.

Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine.

Millar EV, O'Brien KL, Bronsdon MA, Madore D, Hackell JG, Reid R, Santosham M.

Clin Infect Dis. 2007 May 1;44(9):1173-9. Epub 2007 Mar 23.

PMID:
17407035
7.

Evaluation of humoral response to heptavalent pneumococcal conjugate vaccine in HIV-infected children.

Costa Ide C, Guilardi F, Kmiliauskis MA, Arslanian C, Baldacci ER.

Rev Saude Publica. 2008 Oct;42(5):844-50. Epub 2008 Aug 28. English, Portuguese.

8.

Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine.

Dagan R, Melamed R, Muallem M, Piglansky L, Greenberg D, Abramson O, Mendelman PM, Bohidar N, Yagupsky P.

J Infect Dis. 1996 Dec;174(6):1271-8.

PMID:
8940218
9.

Association of Streptococcus pneumoniae common protein antigen (CPA) antibodies and pneumococcal nasopharyngeal colonization in HIV-infected and HIV-uninfected African children.

Ditse Z, Adrian PV, Kuwanda L, Madhi SA.

Vaccine. 2013 Sep 13;31(40):4421-7. doi: 10.1016/j.vaccine.2013.06.097. Epub 2013 Jul 8.

PMID:
23845819
10.

Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals.

Nunes MC, Madhi SA.

Hum Vaccin Immunother. 2012 Feb;8(2):161-73. doi: 10.4161/hv.18432. Epub 2012 Feb 1. Review.

11.

Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial.

Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, Hamilton RG, Musher DM, Nelson KE.

J Infect Dis. 1996 Jan;173(1):83-90.

PMID:
8537687
12.

Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination.

Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE; Adult and Adolescent Spectrum of HIV Disease Project.

Clin Infect Dis. 2001 Mar 1;32(5):794-800. Epub 2001 Feb 28.

PMID:
11229848
13.

Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients.

Breiman RF, Keller DW, Phelan MA, Sniadack DH, Stephens DS, Rimland D, Farley MM, Schuchat A, Reingold AL.

Arch Intern Med. 2000 Sep 25;160(17):2633-8.

PMID:
10999977
14.

Invasive pneumococcal disease among HIV-positive individuals, 2000-2009.

Yin Z, Rice BD, Waight P, Miller E, George R, Brown AE, Smith RD, Slack M, Delpech VC.

AIDS. 2012 Jan 2;26(1):87-94. doi: 10.1097/QAD.0b013e32834dcf27.

PMID:
22008657
15.

Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members.

Millar EV, Watt JP, Bronsdon MA, Dallas J, Reid R, Santosham M, O'Brien KL.

Clin Infect Dis. 2008 Oct 15;47(8):989-96. doi: 10.1086/591966.

PMID:
18781875
16.

Pneumococcal conjugate vaccination in children with recurrent acute otitis media: a therapeutic alternative?

van Kempen MJ, Vermeiren JS, Vaneechoutte M, Claeys G, Veenhoven RH, Rijkers GT, Sanders EA, Dhooge IJ.

Int J Pediatr Otorhinolaryngol. 2006 Feb;70(2):275-85. Epub 2005 Sep 2.

PMID:
16140397
17.

Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.

Zangeneh TT, Baracco G, Al-Tawfiq JA.

Expert Rev Vaccines. 2011 Mar;10(3):345-53. doi: 10.1586/erv.11.1. Review.

PMID:
21434802
18.

Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults.

Lesprit P, Pédrono G, Molina JM, Goujard C, Girard PM, Sarrazin N, Katlama C, Yéni P, Morineau P, Delfraissy JF, Chêne G, Lévy Y; ANRS 114-Pneumovac Study Group.

AIDS. 2007 Nov 30;21(18):2425-34.

PMID:
18025879
19.

Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers.

Dagan R, Givon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, Janco J, Yagupsky P, Fraser D.

J Infect Dis. 2002 Apr 1;185(7):927-36. Epub 2002 Mar 4.

PMID:
11920317
20.

Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian children who participated in a 9-valent pneumococcal conjugate vaccine trial and in their younger siblings.

Cheung YB, Zaman SM, Nsekpong ED, Van Beneden CA, Adegbola RA, Greenwood B, Cutts FT.

Pediatr Infect Dis J. 2009 Nov;28(11):990-5. doi: 10.1097/INF.0b013e3181a78185.

PMID:
19536041

Supplemental Content

Support Center